Currentaspects of psoriasis phototherapy



Cite item

Full Text

Abstract

The review covers current aspects of ultraviolet therapy for patients suffering from psoriasis. It describes mechanisms of action
as well as early and remote side effects of the current phototherapy methods. The review also presents data from literature about
the risk of their cancerogenicity. It also discusses approaches to the optimization of phototherapy in view of risks and benefits for the patient.

References

  1. Fischer T. UV-light treatment of psoriasis. Acta Derm Venereol 1976; 56: 473-479.
  2. Parrish J.A, Jaenicke K.F. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1976; 76: 359-362.
  3. Green C., Ferguson J., Lakshmipathi T., Johnson B.E. 311 nm UVB phototherapy - an effective treatment for psoriasis. Br J Dermatol 1988; 119: 691-696.
  4. Van Weelden H., De La Faille H.B., Young E. et al. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988; 119: 11-19.
  5. Berneburg M., Rocken M., Benedix F. Phototherapy with narrowband versus broadband UVB. Acta Derm Venereol 2005; 85(2): 98-108.
  6. Coven T.R., Burack L.H., Gilleaudeau R. et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadbandUV-B. Arch Dermatol 1997; 133: 1514-1522.
  7. Dawe R.S. A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. Br J Dermatol 2003; 149: 669-672.
  8. Epstein W.L., Fukuyama K., Epstein J.H. Early effects of ultraviolet light on DNA synthesis in human skin in vivo. Arch Dermatol 1969; 100: 84-89.
  9. Gupta G. The efficacy of narrowband UVB phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol 1999; 140(5): 887-890.
  10. Devary Y., Rosette C., Di Donato J.A., Karin N. NF-kB activation by ultraviolet light not dependent on a nuclear signal. Science 1993; 261: 1442-1445.
  11. Averbeck D. Recent advances in psoralen phototoxicity mechanism. Photochem Photobiol 1989; 50: 859-882.
  12. Hearn R.M.R., Kerr A.C., Rahim K.F. et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. J Br J Dermatol 2008; 159(4): 931-935.
  13. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 6: 343-350.
  14. Henseler T., Christophers E., Hönigsmann H., Wolff K. Skin tumors in the European PUVA study: eight year follow-up of 1643 patients treated with PUVA for psoriasis. Am Acad Dermatol 1987; 16: 108-116.
  15. Henseler T., Wolff K., Hönigsmann H., Christophers E. The European PUVA study (EPS) on oral 8-methoxypsoralen photochemotherapy of psoriasis. A cooperative study among 18 European centres. Lancet 1981; 1: 853-857.
  16. Homey B. Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr Drug Targets Inflam Allergy 2004; 3: 169-174.
  17. Ibbotson S.H., Bilsland D., Cox N.H. et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151(2): 283-297.
  18. Johnson R. Staiano-Coico L., Austin L. et al. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63: 566-571.
  19. Kramer D.M., Pathak M.A., Kornhauser A., Wiskemann A. Effects of ultraviolet radiation on biosynthesis of DNA in guinea pig skin. J Invest Dermatol 1974; 62: 388-393.
  20. Lim J.L, Stern R.S. High levels of ultraviolet B exposure increase the risk of nonmelanoma skin cancer in psoralen and ultraviolet Atreated patients. J Invest Dermatol 2005; 124: 505-513.
  21. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005; 44(5): 355-360.
  22. Man I., Crombie I.K., Dawe R.S. et al. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005; 152: 755-757.
  23. Marcil I., Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-1045.
  24. Maier H., Schemper M., Ortel B. et al. Skin tumours in photochemotherapy for psoriasis. A single centre follow-up of 496 patients. Dermatology 1996; 193: 185-191.
  25. Morison W.L., Marwaha S., Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol 1997; 36: 183-185.
  26. Nijsten T., Stern R.S. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-650.
  27. Noonan F.P., De Fabo E.C. Immunosupression by ultraviolet B radiation: initiation by urocanin acid. Immunology Today 1992; 13(7): 250-254.
  28. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291(23): 1207-1211.
  29. Ramos J., Villa J., Ruiz A. et al. UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2006-2011.
  30. Shen J. Modulation of IL-10, IL-12 and IFN-ƒ in the epidermis of hairless mice by UVA (320-400 nm) and UVB (280-320) radiation. J Invest Dermatol 1999; 113(6): 1059-1065.
  31. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994; 73: 2759-2764.
  32. Stern R.S., Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (Psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998;134: 1582-1585.
  33. Stern R.S., Bagheri S., Nichols K. PUVA Follow Up Study. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47(1): 33-39.
  34. Stern R.S., Liebman E.J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 1998; 90: 1278-1284.
  35. Stern R.S. PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44(5): 755-761.
  36. Tanew A., Ortel B., Rappersberger K., Hönigsmann H. 5-methoxypsoralen (Bergapten) for photochemotherapy. J Am Acad Dermatol 1988; 18: 333-338.
  37. Van-de-Kerkhof P.C., De-Rooij M.J. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to longterm acitretin maintenance. Br J Dermatol 1997; 136(2): 275-278.
  38. Calzavara-Pinton P.G., Carlino A., Manfredi E. et al. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol 1994; 186: 164-165.
  39. Vallat V.P., Gilleaudeau P., Battat L. et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180(1): 283-296.
  40. Weichenthal M., Schwarz T. Phototherapy: how does UV workPhotodermatol Photoimmunol Photomed 2005; 21: 260-266.
  41. Warmuth I., Harth Y., Matsui M.S. et al. Ultraviolet radiation induces phosphorylation of the epidermal growth factor receptor. Cancer Res 1994; 54: 374-376.
  42. Wolff K., Hönigsmann H. , Gschnait F. , Konrad K. Photochemotherapie bei Psoriasis. Klinische Erfahrungen bei 152 Patienten. Dtsch Med Wochenschr 1975; 100: 2471-2477.
  43. Weishcer M., Blum A., Eberhard F. et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84: 370-374.
  44. Young A.R., Magnus I.A., Davies A.C., Smith N.P. A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar simulated irradiation. Br J Dermatol 1983; 108: 507-518.
  45. Young A.R. Photochemotherapy and skin carcinogenesis: a critical review. In: A.R. Young, H. Hönigsmann, G. Jori (eds). The fundamental bases of phototherapy. OEMF. Milano 1996; 77-87.
  46. Stern R.S. Actinic degeneration and pigmentary change in association with psoralen and UVA treatment: a 20-year prospective study. J Am Acad Dermatol 2003; 48 (1): 61-67.
  47. Young A.R. Carcinogenicity of UVB phototherapy assessed. Lancet 1995; 345(8962): 1431-1432.
  48. Calzavara-Pinton P.G., Ortel B., Hönigsmann H. et al. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 1994; 189: 256-259.
  49. Turjanmaa K., Salo H., Reunala T. Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis. Acta Derm Venereol (Stockh) 1985; 65: 1: 86-88.
  50. Lowe N.J., Weingarten D., Bourget T., Moy L.S. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J Am Acad Dermatol 1986; 14 (5 Pt 1): 754-760.
  51. Collins P., Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992; 127: 4: 392-395.
  52. Cooper E.J., Herd R.M., Priestley G.C., Hunter J.A.A. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 2000; 25: 2: 111-114.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Zhilova M.B., Butareva M.M., Volnukhin V.A., Zhilova M.B., Butareva M.M., Volnukhin V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies